Octreotide in combination with AT-101 induces cytotoxicity and apoptosis through up-regulation of somatostatin receptors 2 and 5 in DU-145 prostate cancer cells

Simple item page
dc.contributor.authorDegirmenci M.
dc.contributor.authorErdogan A.P.
dc.contributor.authorBulut G.
dc.contributor.authorAtmaca H.
dc.contributor.authorUzunoglu S.
dc.contributor.authorKaraca B.
dc.contributor.authorKarabulut B.
dc.contributor.authorUslu R.
dc.date.accessioned2024-07-22T08:12:13Z
dc.date.available2024-07-22T08:12:13Z
dc.date.issued2016
dc.description.abstractProstate cancer (PCa) is the most common type of cancer among males. Although survival rate of early-stage PCa is high, treatment options are very limited for recurrent disease. In this study, the possible synergistic cytotoxic and apoptotic effect of octreotide in combination with AT-101 was investigated in DU-145 hormone and drug refractory prostate cancer cell line. To enlighten the action mechanisms of the combination treatment, expression levels of somatostatin receptors 2 and 5 (SSTR2 and SSTR5) were also investigated. Cell viability was measured by XTT assay. Apoptosis was assessed through DNA fragmentation analysis and caspase 3/7 assay. mRNA and protein levels of SSTR2 and SSTR5 were evaluated by qRT-PCR and western blot analysis, respectively. Octreotide in combination with AT-101 inhibited cell viability and induced apoptosis synergistically in DU-145 cells as compared to any agent alone. Combination treatment increased both SSTR2 and SSTR5 mRNA and protein levels in DU-145 cells. The data suggest that this combination therapy may be a good candidate for patients with advanced metastatic PCa do not respond to androgen deprivation. © 2015, International Society of Oncology and BioMarkers (ISOBM).
dc.identifier.DOI-ID10.1007/s13277-015-4331-0
dc.identifier.issn10104283
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/15966
dc.language.isoEnglish
dc.publisherSpringer Science and Business Media B.V.
dc.subjectAndrogens
dc.subjectApoptosis
dc.subjectCell Line, Tumor
dc.subjectCell Proliferation
dc.subjectCell Survival
dc.subjectDrug Resistance, Neoplasm
dc.subjectDrug Synergism
dc.subjectGene Expression Regulation, Neoplastic
dc.subjectGossypol
dc.subjectHumans
dc.subjectMale
dc.subjectOctreotide
dc.subjectProstatic Neoplasms
dc.subjectReceptors, Somatostatin
dc.subjectcaspase 3
dc.subjectcaspase 7
dc.subjectisosorbide
dc.subjectmessenger RNA
dc.subjectoctreotide
dc.subjectsomatostatin receptor 2
dc.subjectsomatostatin receptor 5
dc.subjectandrogen
dc.subjectgossypol
dc.subjectgossypol acetic acid
dc.subjectoctreotide
dc.subjectsomatostatin receptor
dc.subjectsomatostatin receptor 2
dc.subjectsomatostatin receptor 5
dc.subjectantineoplastic activity
dc.subjectArticle
dc.subjectcell viability
dc.subjectcontrolled study
dc.subjectDNA fragmentation assay
dc.subjectdrug cytotoxicity
dc.subjectdrug effect
dc.subjectdrug mechanism
dc.subjectDU 145 cancer cell line
dc.subjectenzyme assay
dc.subjecthuman
dc.subjecthuman cell
dc.subjectmale
dc.subjectpriority journal
dc.subjectprostate cancer cell line
dc.subjectprotein determination
dc.subjectprotein function
dc.subjectquantitative analysis
dc.subjectreverse transcription polymerase chain reaction
dc.subjectanalogs and derivatives
dc.subjectapoptosis
dc.subjectbiosynthesis
dc.subjectcell proliferation
dc.subjectcell survival
dc.subjectdrug effects
dc.subjectdrug potentiation
dc.subjectdrug resistance
dc.subjectgene expression regulation
dc.subjectgenetics
dc.subjectmetabolism
dc.subjectpathology
dc.subjectProstatic Neoplasms
dc.subjecttumor cell line
dc.titleOctreotide in combination with AT-101 induces cytotoxicity and apoptosis through up-regulation of somatostatin receptors 2 and 5 in DU-145 prostate cancer cells
dc.typeArticle

Files

Collections

Scopus Koleksiyonu